-
Je něco špatně v tomto záznamu ?
Management of Concomitant Abdominal Aortic Aneurysm and Intra-abdominal, Retroperitoneal Malignancy
V. Treska, J. Molacek, B. Certik, K. Houdek, P. Hosek, V. Soukupova, C. Stogerova, A. Svejdova
Jazyk angličtina Země Řecko
Typ dokumentu časopisecké články
NLK
Free Medical Journals
od 2004 do Před 2 roky
PubMed Central
od 2017
Europe PubMed Central
od 2017
Open Access Digital Library
od 2004-01-01
PubMed
33402504
DOI
10.21873/invivo.12286
Knihovny.cz E-zdroje
- MeSH
- aneurysma břišní aorty * komplikace epidemiologie chirurgie MeSH
- karcinom z renálních buněk * MeSH
- lidé MeSH
- nádory ledvin * MeSH
- nádory žaludku * MeSH
- retroperitoneální nádory * chirurgie MeSH
- senioři MeSH
- výsledek terapie MeSH
- Check Tag
- lidé MeSH
- mužské pohlaví MeSH
- senioři MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
BACKGROUND/AIM: As the population ages, there are increasing findings of coincidental diseases such as abdominal aortic aneurysm (AAA) and intra-abdominal, retroperitoneal malignancy. The aim of this study was to propose an optimal treatment procedure for these patients. PATIENTS AND METHODS: Over a twenty-year-period, surgery was performed on a total of 1,098 patients with AAA and 32 (2.9%) patients with AAA and intra-abdominal, retroperitoneal malignancy: 18 renal, 6 colorectal carcinomas, 3 carcinomas of the small intestine, 3 primary liver tumours, 1 stomach carcinoma and 1 teratoma. The median age of patients was 72.5 years, there were 20 men (62.5%) and 12 women (37.5%). A one-stage procedure was performed on 19 patients (59.4%), and a two-stage procedure on 13 (40.6%) patients. RESULTS: The average time of hospitalization was 12.4±6.9 days (median=11.0 days) for one-stage procedure, for a two-stage procedure 21.3±9.3 days (median=20.0 days), p=0.0045. Seven patients (21.9%) died within 30 days after the operation. All the deaths were in the group of one-stage procedures (p=0.0252). The 1-, 3- and 5-year overall survival for patients following one-stage and twostage procedures was 61.0/56.3/51.5% and 89.0/79.9/53.0% respectively (p=0.1199). CONCLUSION: Symptomatic disease must be resolved first. Two-stage procedures are the method of choice and offer better short-term results compared to one-stage procedures.
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc21019542
- 003
- CZ-PrNML
- 005
- 20230222093451.0
- 007
- ta
- 008
- 210728s2021 gr f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.21873/invivo.12286 $2 doi
- 035 __
- $a (PubMed)33402504
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a gr
- 100 1_
- $a Treska, Vladislav $u Department of Surgery, School of Medicine in Pilsen, Charles University in Prague, Prague, Prague, Czech Republic; treska@fnplzen.cz
- 245 10
- $a Management of Concomitant Abdominal Aortic Aneurysm and Intra-abdominal, Retroperitoneal Malignancy / $c V. Treska, J. Molacek, B. Certik, K. Houdek, P. Hosek, V. Soukupova, C. Stogerova, A. Svejdova
- 520 9_
- $a BACKGROUND/AIM: As the population ages, there are increasing findings of coincidental diseases such as abdominal aortic aneurysm (AAA) and intra-abdominal, retroperitoneal malignancy. The aim of this study was to propose an optimal treatment procedure for these patients. PATIENTS AND METHODS: Over a twenty-year-period, surgery was performed on a total of 1,098 patients with AAA and 32 (2.9%) patients with AAA and intra-abdominal, retroperitoneal malignancy: 18 renal, 6 colorectal carcinomas, 3 carcinomas of the small intestine, 3 primary liver tumours, 1 stomach carcinoma and 1 teratoma. The median age of patients was 72.5 years, there were 20 men (62.5%) and 12 women (37.5%). A one-stage procedure was performed on 19 patients (59.4%), and a two-stage procedure on 13 (40.6%) patients. RESULTS: The average time of hospitalization was 12.4±6.9 days (median=11.0 days) for one-stage procedure, for a two-stage procedure 21.3±9.3 days (median=20.0 days), p=0.0045. Seven patients (21.9%) died within 30 days after the operation. All the deaths were in the group of one-stage procedures (p=0.0252). The 1-, 3- and 5-year overall survival for patients following one-stage and twostage procedures was 61.0/56.3/51.5% and 89.0/79.9/53.0% respectively (p=0.1199). CONCLUSION: Symptomatic disease must be resolved first. Two-stage procedures are the method of choice and offer better short-term results compared to one-stage procedures.
- 650 _2
- $a senioři $7 D000368
- 650 12
- $a aneurysma břišní aorty $x komplikace $x epidemiologie $x chirurgie $7 D017544
- 650 12
- $a karcinom z renálních buněk $7 D002292
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a lidé $7 D006801
- 650 12
- $a nádory ledvin $7 D007680
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 12
- $a retroperitoneální nádory $x chirurgie $7 D012186
- 650 12
- $a nádory žaludku $7 D013274
- 650 _2
- $a výsledek terapie $7 D016896
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Molacek, Jiri $u Department of Surgery, School of Medicine in Pilsen, Charles University in Prague, Prague, Prague, Czech Republic
- 700 1_
- $a Certik, Bohuslav $u Department of Surgery, School of Medicine in Pilsen, Charles University in Prague, Prague, Prague, Czech Republic
- 700 1_
- $a Houdek, Karel $u Department of Surgery, School of Medicine in Pilsen, Charles University in Prague, Prague, Prague, Czech Republic
- 700 1_
- $a Hosek, Petr $u Biomedicine Center, School of Medicine, Pilsen, Czech Republic
- 700 1_
- $a Soukupová, Veronika $u Department of Surgery, School of Medicine in Pilsen, Charles University in Prague, Prague, Prague, Czech Republic $7 xx0282376
- 700 1_
- $a Stogerova, Christiana $u Department of Surgery, School of Medicine in Pilsen, Charles University in Prague, Prague, Prague, Czech Republic
- 700 1_
- $a Svejdova, Aneta $u Department of Surgery, School of Medicine in Pilsen, Charles University in Prague, Prague, Prague, Czech Republic
- 773 0_
- $w MED00175831 $t In Vivo $x 1791-7549 $g Roč. 35, č. 1 (2021), s. 517-523
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/33402504 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y p $z 0
- 990 __
- $a 20210728 $b ABA008
- 991 __
- $a 20230222093446 $b ABA008
- 999 __
- $a ok $b bmc $g 1690384 $s 1139988
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2021 $b 35 $c 1 $d 517-523 $e - $i 1791-7549 $m In Vivo $n In Vivo $x MED00175831
- LZP __
- $a Pubmed-20210728